Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · S

S. 2055 (114th)

Medical Countermeasure Innovation Act of 2016

openUnited States· United States Congress· EN

Introduced

17 September 2015

Last action

14 March 2016 · Reported

Status

Placed on Senate Legislative Calendar under General Orders. Calendar No. 388.

Sponsors

Sen. Burr, Richard [R-NC], Sen. Casey, Robert P., Jr. [D-PA], Sen. Isakson, Johnny [R-GA], Sen. Roberts, Pat [R-KS], Sen. Alexander, Lamar [R-TN]

Subjects

Healthcare, Budget

Source updated

21 April 2025

Healthcare · Budget

Summary

Medical Countermeasure Innovation Act of 2015 This bill amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to ensure the issuance of timely and accurate guidelines regarding the use of medical products for countering public health emergencies or material threats. The Biomedical Advanced Research and Development Authority's contracting authority for procurement of medical countermeasures under Project BioShield is codified. Such procurement no longer requires Presidential approval or an agreement between HHS and the Department of Homeland Security. The Office of the Assistant Secretary for Preparedness and Response must publish its budget plan for medical countermeasures. This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to explain delays in finalizing guidance regarding development of animal models to support approval of medical countermeasures. Upon approval, the FDA must award a priority review voucher to the sponsor of a drug or biological product that: (1) is a significant improvement in the prevention, diagnosis, or treatment of a serious condition; and (2) can be used as a medical countermeasure to a material threat. The transferable voucher entitles the holder to have a new medication application acted upon by the FDA within six months. The sponsor of a medication that is subject to a voucher must pay a user fee based on the FDA's cost for the priority review process. The FDA must publish a notice each time it issues a voucher or a voucher is used.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 17 September 2015

    Introduced

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Source: IntroReferral

  2. 17 September 2015

    Introduced

    Introduced in Senate

    Source: IntroReferral

  3. 9 March 2016

    Reported

    Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

    Source: Committee

  4. 14 March 2016

    Calendars

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 388.

    Source: Calendars

  5. 14 March 2016

    Reported

    Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.

    Source: Committee

  6. 14 March 2016

    Reported

    Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

6 official files

Reported to Senate (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Reported to Senate (text)

    Reported to Senate · EN · 14 March 2016

    ViewDownloadOpen at official source

  • Reported to Senate (PDF)

    Reported to Senate · EN · 14 March 2016

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Reported to Senate with amendment(s)

    summary · EN · 14 March 2016

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate (text)

    Introduced in Senate · EN · 17 September 2015

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate (PDF)

    Introduced in Senate · EN · 17 September 2015

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate

    summary · EN · 17 September 2015

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.